Newron extends EIB loan maturities to align financing with Evenamide milestones

Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an update.

Newron Pharmaceuticals has reached an agreement in principle with the European Investment Bank to extend the maturity of all outstanding tranches under its 2018 finance contract to 28 June 2028. The modification, which remains subject to definitive documentation and additional conditions, effectively lengthens the company’s debt profile and aligns repayments with the expected timeline of key milestones for its lead schizophrenia candidate, Evenamide.

Management highlighted that the extended repayment period supports Newron’s ability to advance the registration-enabling Phase III ENIGMA-TRS program for treatment-resistant schizophrenia without near-term financing pressure. The move strengthens financial flexibility at a critical stage of clinical development, potentially reinforcing Newron’s position in CNS drug development and providing added visibility for partners and investors focused on the progress of Evenamide and the company’s broader neuroscience pipeline.

The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF21.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.

More about Newron Pharmaceuticals SpA

Newron Pharmaceuticals is a biopharmaceutical company specializing in therapies for central and peripheral nervous system disorders, headquartered in Bresso near Milan, Italy. Its lead candidate Evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia, is in a global Phase III program, while its marketed drug Xadago treats Parkinson’s disease through partners across Europe, North America and Asia.

The company has established development and marketing collaborations for Evenamide with EA Pharma in Japan and other Asian territories and with Myung In Pharm in South Korea. Xadago is commercialized by partner Zambon in multiple regions, with Supernus Pharmaceuticals holding U.S. rights and Meiji Seika responsible for Japan and key Asian markets, underscoring Newron’s partnership-driven commercialization strategy.

Average Trading Volume: 146,941

Technical Sentiment Signal: Buy

Current Market Cap: CHF324.3M

See more insights into NWRN stock on TipRanks’ Stock Analysis page.